THE EFFECT OF NASAL hCT ON BONE TURNOVER IN PAGET'S DISEASE OF BONE—IMPLICATIONS FOR THE TREATMENT OF OTHER METABOLIC BONE DISEASES

1 January 1992

journal article
research article
Published by Oxford University Press (OUP) in Rheumatology

Vol. 31 (1) , 35-39
https://doi.org/10.1093/rheumatology/31.1.35

Abstract

Thirty pagetic patients were treated for 6 months with a daily nasal application of 2 mg of synthetic human calcitonin (hCT). Serum alkaline phosphatases (SAP) and urinary hydroxyproline/creatinine ratio (OH/Cr), reflecting bone turn over, were significantly reduced from the first month of treatment (mean ± SEM: SAP, −13.9 ± 2.2%; OH/Cr, −22.2 ± 5.8%; both P.<0.01) and until the end of the 6-month course (mean ± SEM: SAP, −29.7 ± 4.6%; OH/Cr, −22.5 ± 5.9%; both P<0.01). Nasal hCT was perfectly tolerated both locally and systemically. These results allow us to consider nasal hCT for long-term trials in metabolic bone diseases characterized by a relative increase of bone resorption.

Keywords

This publication has 0 references indexed in Scilit: